Su Cheng, Li Cai, Hu Xinyi, Wang Jing, Liu Linlin, Zhang Xianfeng, Tong Yeqing
School of Public Health, Huazhong University of Science and Technology, Wuhan, Hubei, People's Republic of China.
Infectious Disease Prevention and Control Center, Wuhan Center for Disease Control and Prevention, Wuhan, Hubei, People's Republic of China.
Infect Drug Resist. 2024 May 7;17:1771-1780. doi: 10.2147/IDR.S445180. eCollection 2024.
Angiotensin-converting enzyme 2 (ACE2) is an important regulator of the Renin-Angiotensin System (RAS). Additionally, it has been identified as a functional receptor for the Coronavirus. Research indicates that ACE2 plays a role in the regulation of cardiovascular systems by modulating blood pressure and electrolyte balance. Its role in pulmonary diseases has also garnered significant attention due to the widespread prevalence of Coronavirus. There is solid evidence linking ACE2 to other pulmonary diseases, including chronic obstructive pulmonary disease, acute respiratory distress syndrome, allergic asthma, among others. However, the exact pathological and physiological mechanisms of ACE2 in these diseases remain elusive. Our research aims to review and explore the latest advancements in ACE2-related studies in pulmonary diseases. These findings have the potential to open new avenues for utilizing ACE2 as a potential biomarker for early diagnosis and monitoring of pulmonary diseases.
血管紧张素转换酶2(ACE2)是肾素-血管紧张素系统(RAS)的重要调节因子。此外,它已被确定为冠状病毒的功能性受体。研究表明,ACE2通过调节血压和电解质平衡在心血管系统调节中发挥作用。由于冠状病毒的广泛流行,其在肺部疾病中的作用也备受关注。有确凿证据表明ACE2与其他肺部疾病有关,包括慢性阻塞性肺疾病、急性呼吸窘迫综合征、过敏性哮喘等。然而,ACE2在这些疾病中的确切病理生理机制仍不清楚。我们的研究旨在回顾和探索肺部疾病中ACE2相关研究的最新进展。这些发现有可能为将ACE2用作肺部疾病早期诊断和监测的潜在生物标志物开辟新途径。